HC-1119 COMPOSITION, ITS PRODUCTION METHOD AND USE Russian patent published in 2022 - IPC A61K31/4166 A61K9/48 A61P35/00 

FIELD: pharmaceutics.

SUBSTANCE: group of inventions relates to the field of pharmaceutics; it can be used for the treatment of diseases depending on the androgen signaling path, including prostate cancer and breast cancer. A composition of HC-1119 androgen receptor inhibitor is proposed, obtained from ingredients with the following mass ratio: 1-100 parts of HC-1119 androgen receptor inhibitors, 100-1000 parts of a solvent, and 0.11-11 parts of an antioxidant, where the solvent is a combination of one or more of labrazole, polyethylene glycol, polyethylene glycol glyceride, and caprylic/caprine glyceride, and the antioxidant is a combination of one or more of butylhydroxyanisole and butylhydroxytoluene. The group of inventions also relates to a soft capsule containing the specified composition, methods for the production of a composition and a capsule, as well as the use of a composition and a capsule for the production of a drug for the treatment of diseases depending on the androgen signaling path, and methods for the treatment of the specified diseases.

EFFECT: HC-1119 composition is proposed with improved solubility, increased bioavailability and safety, which reduces the difference between the residual concentration of a drug in blood and the level in plasma.

27 cl, 5 tbl, 4 ex